TuHURA Biosciences, Inc. (NASDAQ:HURA) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of TuHURA Biosciences, Inc. (NASDAQ:HURA) have received a consensus rating of “Moderate Buy” from the six research firms that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation and five have assigned a buy recommendation to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $9.00.

A number of equities analysts recently commented on HURA shares. Rodman & Renshaw started coverage on shares of TuHURA Biosciences in a research note on Wednesday, April 15th. They set a “buy” rating for the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of TuHURA Biosciences in a research note on Tuesday, April 21st. Wall Street Zen downgraded shares of TuHURA Biosciences from a “hold” rating to a “sell” rating in a research note on Sunday, May 31st. Citigroup started coverage on shares of TuHURA Biosciences in a research note on Monday, April 27th. They set an “outperform” rating for the company. Finally, Citizens Jmp started coverage on shares of TuHURA Biosciences in a research note on Monday, April 27th. They set a “market outperform” rating and a $9.00 target price for the company.

Hedge Funds Weigh In On TuHURA Biosciences

Several large investors have recently bought and sold shares of the stock. Bank of America Corp DE boosted its stake in TuHURA Biosciences by 24.0% in the first quarter. Bank of America Corp DE now owns 78,142 shares of the company’s stock valued at $140,000 after acquiring an additional 15,135 shares in the last quarter. Greenline Wealth Management LLC acquired a new position in TuHURA Biosciences in the first quarter valued at $66,000. Merck & Co. Inc. boosted its stake in TuHURA Biosciences by 39.4% in the first quarter. Merck & Co. Inc. now owns 19,445 shares of the company’s stock valued at $35,000 after acquiring an additional 5,495 shares in the last quarter. Cetera Investment Advisers acquired a new position in TuHURA Biosciences in the first quarter valued at $251,000. Finally, WealthShield Partners LLC acquired a new position in TuHURA Biosciences in the first quarter valued at $164,000. Institutional investors and hedge funds own 0.62% of the company’s stock.

TuHURA Biosciences Trading Up 3.0%

TuHURA Biosciences stock opened at $2.23 on Monday. TuHURA Biosciences has a twelve month low of $0.41 and a twelve month high of $3.90. The stock’s fifty day simple moving average is $2.39 and its 200-day simple moving average is $1.65. The firm has a market capitalization of $141.69 million, a P/E ratio of -3.65 and a beta of 0.01.

TuHURA Biosciences (NASDAQ:HURA) last issued its earnings results on Friday, May 15th. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01). Sell-side analysts predict that TuHURA Biosciences will post -0.56 earnings per share for the current year.

TuHURA Biosciences Company Profile

TuHURA Biosciences is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics using high‐dimensional proteomics. The company’s core mission is to translate complex protein signatures into actionable drug targets across a range of disease areas. By integrating proteomic data with advanced computational analytics, TuHURA aims to bridge the gap between molecular disease understanding and the development of first‐in‐class therapies.

At the heart of TuHURA’s approach is its proprietary platform, which leverages multiplexed protein profiling to generate rich phenotypic maps of disease states.